Grants > Next-Generation Glaucoma Drugs to Selectively Release the Pressure-Building Block in Schlemm’s Canal
Updated On: Jun 26, 2025
National Glaucoma Research Grant
Next-Generation Glaucoma Drugs to Selectively Release the Pressure-Building Block in Schlemm’s Canal
Controlling Eye Pressure in New Ways
About the Research Project
Program
National Glaucoma Research
Award Type
Bold Ideas initiatives
Award Amount
$513,366
Active Dates
March 31, 2021 - February 28, 2025
Grant ID
CG2020001
Acknowledgement
Part A of Joint Research Award for a Collaborative Interinstitutional Grant.
Goals
We now understand that endothelial cells of the inner wall of Schlemm’s canal (SC) play a key role in homeostatic control mechanisms that maintain IOP within a target range. The long-term goal of this project is to develop novel therapies that directly target SC cells to improve IOP control. These targeted therapies will be highly effective due their specificity, and will thus greatly benefit glaucoma patients.
Related Grants
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
IOP-Related Gene Responses in the Optic Nerve Head and Trabecular Meshwork
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Diana C. Lozano, PhD
Current Organization
Oregon Health & Science University